JNCI Journal of the National Cancer Institute · 1977 · 28 citations · 0 references
MedicinePharmacologyToxicologyCancer Drug Toxicity ManagementChemotherapyRadiobiologyGastrointestinal ToxicityHematopoietic ToxicityAcute Drug ToxicityAcute Tissue ToxicityBone Marrow Cellular ToxicityMethotrexate Toxicity PreventionPurine ChemistryPurine Degradation
Thymidine, in the absence of hypoxanthine, failed to protect normal mice from the acute toxicity of methotrexate, though tumor-bearing animals could be protected with thymidine alone, probably as a result of the availability of DNA degradation products released from drug-sensitive tumor cells. Although metrotrexate induced an early purine deficiency in gut cells, this effect was not detected in bone marrow. Later, purine deficiency became apparent in the gut and bone marrow of methotrexate-treated animals.